Results for the First Quarter 2023

Strong sales for the first quarter at MNOK 129.3 (MNOK 116.1) due to favorable currency. Currency neutral growth was 1.2%.

‍

NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral growth of own products was 2.5%. Operating profit (EBIT) for the quarter ended at MNOK 33.5, an EBIT margin of 25.9% (MNOK 33.4 or 28.8%). Medistim establishes direct sales organizations in both Canada and China this quarter.
‍

Download the full presentation and report and watch the video recording from the webinar below.
‍

588393_Quarterly Report Q1 2023
‍
‍‍588393_Medistim ASA Q1 2023 Presentation
‍